공고 • May 15
genXone S.A., Annual General Meeting, Jun 23, 2026 genXone S.A., Annual General Meeting, Jun 23, 2026, at 13:00 Central European Standard Time. Reported Earnings • Feb 17
Full year 2025 earnings released: zł0.65 loss per share (vs zł1.19 loss in FY 2024) Full year 2025 results: zł0.65 loss per share (improved from zł1.19 loss in FY 2024). Revenue: zł2.34m (up 31% from FY 2024). Net loss: zł2.14m (loss narrowed 45% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 17% per year whereas the company’s share price has fallen by 22% per year. 공고 • Feb 09
genXone S.A. to Report Q4, 2025 Results on Feb 11, 2026 genXone S.A. announced that they will report Q4, 2025 results on Feb 11, 2026 Reported Earnings • Nov 18
Third quarter 2025 earnings released Third quarter 2025 results: Revenue: zł509.1k (up 5.5% from 3Q 2024). Net loss: zł644.0k (loss narrowed 16% from 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 62% per year but the company’s share price has only fallen by 26% per year, which means it has not declined as severely as earnings. 공고 • Nov 10
genXone S.A. to Report Q3, 2025 Results on Nov 12, 2025 genXone S.A. announced that they will report Q3, 2025 results on Nov 12, 2025 New Risk • Jun 08
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 7.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 49% per year over the past 5 years. Revenue is less than US$1m (zł1.9m revenue, or US$502k). Market cap is less than US$10m (zł20.4m market cap, or US$5.42m). Minor Risk Share price has been volatile over the past 3 months (7.4% average weekly change). 공고 • May 27
genXone S.A., Annual General Meeting, Jun 23, 2025 genXone S.A., Annual General Meeting, Jun 23, 2025. Reported Earnings • May 16
First quarter 2025 earnings released First quarter 2025 results: Revenue: zł427.1k (up 32% from 1Q 2024). Net loss: zł732.3k (loss narrowed 16% from 1Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 85 percentage points per year, which is a significant difference in performance. New Risk • Jan 13
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (9.5% average weekly change). Market cap is less than US$10m (zł19.4m market cap, or US$4.65m). New Risk • Jan 02
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Polish stocks, typically moving 9.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.0% average weekly change). Earnings have declined by 33% per year over the past 5 years. Revenue is less than US$1m (zł1.7m revenue, or US$419k). Market cap is less than US$10m (zł22.1m market cap, or US$5.32m). New Risk • Jun 17
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Polish stocks, typically moving 9.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.1% average weekly change). Earnings have declined by 13% per year over the past 5 years. Revenue is less than US$1m (zł2.0m revenue, or US$492k). Market cap is less than US$10m (zł19.5m market cap, or US$4.77m). 공고 • May 25
genXone S.A., Annual General Meeting, Jun 18, 2024 genXone S.A., Annual General Meeting, Jun 18, 2024. Reported Earnings • Feb 15
Full year 2023 earnings released: zł1.13 loss per share (vs zł0.15 profit in FY 2022) Full year 2023 results: zł1.13 loss per share (down from zł0.15 profit in FY 2022). Revenue: zł2.39m (down 77% from FY 2022). Net loss: zł3.72m (down zł4.20m from profit in FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 54 percentage points per year, which is a significant difference in performance. Reported Earnings • Aug 13
Second quarter 2023 earnings released Second quarter 2023 results: Revenue: zł766.1k (down 62% from 2Q 2022). Net loss: zł817.9k (loss widened 294% from 2Q 2022). 공고 • May 26
genXone S.A., Annual General Meeting, Jun 19, 2023 genXone S.A., Annual General Meeting, Jun 19, 2023, at 11:00 Central European Standard Time. Valuation Update With 7 Day Price Move • May 08
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to zł10.25, the stock trades at a trailing P/E ratio of 70.3x. Average trailing P/E is 66x in the Biotechs industry in Poland. Total loss to shareholders of 30% over the past year. Reported Earnings • Feb 13
Full year 2022 earnings released: EPS: zł0.15 (vs zł2.66 in FY 2021) Full year 2022 results: EPS: zł0.15 (down from zł2.66 in FY 2021). Revenue: zł10.6m (down 54% from FY 2021). Net income: zł480.3k (down 95% from FY 2021). Profit margin: 4.5% (down from 38% in FY 2021). The decrease in margin was driven by lower revenue. Valuation Update With 7 Day Price Move • Jan 02
Investor sentiment improved over the past week After last week's 20% share price gain to zł11.80, the stock trades at a trailing P/E ratio of 7.5x. Average trailing P/E is 47x in the Biotechs industry in Poland. Total loss to shareholders of 41% over the past year. Reported Earnings • Aug 16
Second quarter 2022 earnings released Second quarter 2022 results: Revenue: zł1.99m (down 68% from 2Q 2021). Net loss: zł207.8k (down 110% from profit in 2Q 2021). Upcoming Dividend • Jun 10
Upcoming dividend of zł1.00 per share Eligible shareholders must have bought the stock before 17 June 2022. Payment date: 04 July 2022. Payout ratio is a comfortable 38% and this is well supported by cash flows. Trailing yield: 6.4%. Lower than top quartile of Polish dividend payers (7.8%). Higher than average of industry peers (1.4%). Valuation Update With 7 Day Price Move • Jun 02
Investor sentiment improved over the past week After last week's 19% share price gain to zł17.26, the stock trades at a trailing P/E ratio of 6.6x. Average trailing P/E is 25x in the Biotechs industry in Poland. Total loss to shareholders of 32% over the past year. 공고 • May 10
genXone S.A., Annual General Meeting, Jun 06, 2022 genXone S.A., Annual General Meeting, Jun 06, 2022, at 12:00 Central European Standard Time. Valuation Update With 7 Day Price Move • Feb 24
Investor sentiment deteriorated over the past week After last week's 21% share price decline to zł15.02, the stock trades at a trailing P/E ratio of 5.6x. Average trailing P/E is 33x in the Biotechs industry in Poland. Total loss to shareholders of 55% over the past year. Reported Earnings • Feb 13
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: EPS: zł2.66 (up from zł2.17 in FY 2020). Revenue: zł23.4m (up 14% from FY 2020). Net income: zł8.78m (up 23% from FY 2020). Profit margin: 38% (up from 35% in FY 2020). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Valuation Update With 7 Day Price Move • Jan 24
Investor sentiment deteriorated over the past week After last week's 17% share price decline to zł19.20, the stock trades at a trailing P/E ratio of 7.1x. Average trailing P/E is 48x in the Biotechs industry in Poland. Total loss to shareholders of 28% over the past year. Valuation Update With 7 Day Price Move • Sep 03
Investor sentiment improved over the past week After last week's 15% share price gain to zł33.20, the stock trades at a trailing P/E ratio of 15.3x. Average trailing P/E is 81x in the Biotechs industry in Poland. Total loss to shareholders of 21% over the past year. 공고 • Jun 08
An unknown buyer acquired 14.3% stake in genXone S.A. (WSE:GX1) from Torox Eko FIZAN, fund managed by AgioFunds Towarzystwo Funduszy Inwestycyjnych S.A. An unknown buyer acquired 14.3% stake in genXone S.A. (WSE:GX1) from Torox Eko FIZAN, fund managed by AgioFunds Towarzystwo Funduszy Inwestycyjnych S.A. on June 4, 2021.
An unknown buyer completed the acquisition of 14.3% stake in genXone S.A. (WSE:GX1) from Torox Eko FIZAN, fund managed by AgioFunds Towarzystwo Funduszy Inwestycyjnych S.A. on June 4, 2021. Is New 90 Day High Low • Feb 26
New 90-day high: zł35.20 The company is up 21% from its price of zł29.00 on 27 November 2020. The Polish market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 6.0% over the same period. Reported Earnings • Feb 14
Full year 2020 earnings released: EPS zł2,172 The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: zł20.5b (up zł20.3b from FY 2019). Net income: zł7.16b (up zł8.23b from FY 2019). Profit margin: 35% (up from net loss in FY 2019). The move to profitability was driven by higher revenue. Is New 90 Day High Low • Dec 24
New 90-day low: zł20.80 The company is down 24% from its price of zł27.37 on 24 September 2020. The Polish market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 17% over the same period. 공고 • Sep 06
genXone S.A. to Report Q3, 2020 Results on Nov 13, 2020 genXone S.A. announced that they will report Q3, 2020 results on Nov 13, 2020